Khanna, Dinesh https://orcid.org/0000-0003-1412-4453
Allanore, Yannick
Denton, Christopher P https://orcid.org/0000-0003-3975-8938
Kuwana, Masataka https://orcid.org/0000-0001-8352-6136
Matucci-Cerinic, Marco
Pope, Janet E https://orcid.org/0000-0003-1479-5302
Atsumi, Tatsuya
Bečvář, Radim
Czirják, László
Hachulla, Eric
Ishii, Tomonori
Ishikawa, Osamu
Johnson, Sindhu R https://orcid.org/0000-0003-0591-2976
De Langhe, Ellen
Stagnaro, Chiara
Riccieri, Valeria
Schiopu, Elena
Silver, Richard M https://orcid.org/0000-0002-2038-3278
Smith, Vanessa
Steen, Virginia
Stevens, Wendy
Szücs, Gabriella
Truchetet, Marie-Elise
Wosnitza, Melanie
Laapas, Kaisa
de Oliveira Pena, Janethe
Yao, Zhen
Kramer, Frank
Distler, Oliver https://orcid.org/0000-0002-0546-8310
Clinical trials referenced in this document:
Documents that mention this clinical trial
Protein kinases G are essential downstream mediators of the antifibrotic effects of sGC stimulators
https://doi.org/10.1136/annrheumdis-2017-212489
OP0249 LONG-TERM EXTENSION RESULTS OF RISE-SSC, A RANDOMIZED TRIAL OF RIOCIGUAT IN PATIENTS WITH EARLY DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS (DCSSC)
https://doi.org/10.1136/annrheumdis-2020-eular.3671
FRI0303 THE EFFECTS OF RIOCIGUAT ON RAYNAUD'S PHENOMENON AND DIGITAL ULCERS IN PATIENTS WITH DIFFUSE SYSTEMIC SCLEROSIS: RESULTS FROM THE PHASE IIB RISE-SSC STUDY
https://doi.org/10.1136/annrheumdis-2019-eular.5755
OP0183 EFFICACY AND SAFETY OF RIOCIGUAT IN PATIENTS WITH EARLY DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS AND INTERSTITIAL LUNG DISEASE (SSC-ILD): RESULTS FROM THE PHASE IIB RISE-SSC STUDY
https://doi.org/10.1136/annrheumdis-2019-eular.6889
AB0627 Rise-ssc: a double-blind, randomised study evaluating the efficacy and safety of riociguat for the treatment of patients with diffuse cutaneous systemic sclerosis
https://doi.org/10.1136/annrheumdis-2017-eular.3718
Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): randomised, double-blind, placebo-controlled multicentre trial
https://doi.org/10.1136/annrheumdis-2019-216823
Riociguat for the treatment of pulmonary arterial hypertension associated with connective tissue disease: results from PATENT-1 and PATENT-2
https://doi.org/10.1136/annrheumdis-2015-209087
FRI0575 BIOMARKER ANALYSIS FROM THE RISE-SSC STUDY OF RIOCIGUAT IN EARLY DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS (DCSSC)
https://doi.org/10.1136/annrheumdis-2020-eular.3138
Funding for this research was provided by:
Bayer AG
This article is maintained by: Elsevier
Article Title: Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): randomised, double-blind, placebo-controlled multicentre trial
Journal Title: Annals of the Rheumatic Diseases
CrossRef DOI link to publisher maintained version: https://doi.org/10.1136/annrheumdis-2019-216823
Content Type: article
Copyright: Copyright © 2020 © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY. Published by Elsevier Inc. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.